Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06789848 · ClinicalTrials.gov registry record · Phase 2
Ligufalimab and Cadonilimab in Advanced Liver Cancers
A Phase 2 study of Biliary Tract Cancer and Advanced Hepatocellular Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06789848 is a Phase 2 study of Biliary Tract Cancer and Advanced Hepatocellular Carcinoma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 64 participants, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06789848, a Phase 2 study of Biliary Tract Cancer and Advanced Hepatocellular Carcinoma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
Conditions Studied
Interventions
- DRUG Ligufalimab
- DRUG Cadonilimab
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2030-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06789848
The ClinicalTrials.gov registry entry for NCT06789848 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (73% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Biliary Tract Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ligufalimab is the first listed.
NCT06789848 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06789848 about?
NCT06789848 is a clinical study titled "Ligufalimab and Cadonilimab in Advanced Liver Cancers". The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
What is the current status of trial NCT06789848?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2025-02-18. Estimated completion is 2030-05-31.
What conditions does trial NCT06789848 study?
This clinical trial studies the following conditions: Biliary Tract Cancer, Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06789848?
The interventions under investigation include: Ligufalimab (DRUG), Cadonilimab (DRUG).
Who is sponsoring clinical trial NCT06789848?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06789848 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
RECRUITING · Phase 2
-
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RECRUITING · Phase 2
-
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.